Latest News on BIO

Financial News Based On Company


Advertisement
Advertisement

Form 4 BIO-RAD LABORATORIES: James Barry (EVP, President, LSG) For: 9 November

https://ca.investing.com/news/stock-market-news/form-4-biorad-laboratories-james-barry-evp-president-lsg-for-9-november-93CH-4958756
This article reports on a Form 4 filing for Bio-Rad Laboratories concerning James Barry, EVP, President, LSG, for transactions on November 9. Form 4 filings are regulatory documents used to disclose changes in beneficial ownership of a company's securities by insiders. The article also provides current stock market data, including various indices, commodities, and individual stock performances.

Form 4 BIO-RAD LABORATORIES: James Barry (EVP, President, LSG) For: 9 November

https://uk.investing.com/news/stock-market-news/form-4-biorad-laboratories-james-barry-evp-president-lsg-for-9-november-93CH-4982778
This article reports on a Form 4 filing for Bio-Rad Laboratories concerning James Barry, EVP, President, LSG, with a transaction date of November 9. Form 4s disclose changes in beneficial ownership of company stock by insiders. The article mentions the stock symbol BIO and its performance at -1.11%.

Form 4 BIO-RAD LABORATORIES: Jonathan P. DiVincenzo (President & COO) For: 9 November

https://uk.investing.com/news/stock-market-news/form-4-biorad-laboratories-jonathan-p-divincenzo-president--coo-for-9-november-93CH-4978359
This article reports on a Form 4 filing for Bio-Rad Laboratories concerning Jonathan P. DiVincenzo, the company's President & COO, for activity on November 9. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The article indicates this is a standard regulatory disclosure.

Form 4 BIO-RAD LABORATORIES: Jonathan P. DiVincenzo (President & COO) For: 9 November

https://ca.investing.com/news/stock-market-news/form-4-biorad-laboratories-jonathan-p-divincenzo-president--coo-for-9-november-93CH-4953780
The article reports on a Form 4 filing for Bio-Rad Laboratories concerning Jonathan P. DiVincenzo, who serves as President & COO, for activity on November 9. Form 4s disclose changes in beneficial ownership of company stock by insiders. This filing indicates an insider transaction by a key executive at Bio-Rad Laboratories.

Form 144 BIO-RAD LABORATORIES For: 11 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-biorad-laboratories-for-11-november-93CH-2799071
This article reports on the filing of Form 144 for Bio-Rad Laboratories on November 11. Form 144 is a notice of the intent to sell restricted securities. The brief article, published by Investing.com, indicates the specific date of the filing for the company, BIO.
Advertisement

Form 144 BIO-RAD LABORATORIES For: 9 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-biorad-laboratories-for-9-november-93CH-4970253
The article reports on a Form 144 filing for Bio-Rad Laboratories, specifically dated for November 9th. Published by Investing.com, the brief notice indicates a regulatory filing related to the company's stock.

BIO.B SEC Filings, Apr-May 2026 - BIO-RAD LABORATORIES, INC. Filing Archive

https://www.stocktitan.net/sec-filings/BIO.B/page-3.html
This article archives SEC filings for Bio-Rad Laboratories (BIO.B) from April to May 2026, detailing insider trading, quarterly reports, and corporate governance actions. Key events include an EVP selling A shares, Morgan Stanley's Rule 144 notice, Bio-Rad's Q1 2026 net loss driven by a large Sartorius holding loss, and the approval of incentive plan changes by shareholders. The company also trimmed its full-year 2026 guidance.

$459M in net income comes alongside an operating loss at Bio-Rad (BIO).

https://www.stocktitan.net/sec-filings/BIO/10-q-bio-rad-laboratories-inc-quarterly-earnings-report-c49b56ecb456.html
Bio-Rad Laboratories, Inc. reported a Q3 2026 net income of $458.6 million, a significant turnaround from a $341.9 million net loss a year prior, primarily due to a $583.2 million holding gain on its Sartorius investment. Despite this, the company posted an operating loss of $49.7 million, including a $49.8 million impairment of Celsee-related intangible assets, and incurred $77.6 million in restructuring costs. Net sales for the quarter were $656.4 million, a slight increase of 0.5% year-over-year.

BIO.B SEC Filings - BIO-RAD LABORATORIES, INC. 10-K, 10-Q, 8-K Forms

https://www.stocktitan.net/sec-filings/BIO.B/
This article provides a compilation of recent SEC filings for Bio-Rad Laboratories, Inc. (BIO.B), including 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Key filings highlight the company's Q3 2026 financial performance, a restructuring plan, and insider stock transactions by executives and directors. Each filing is accompanied by an AI-generated summary detailing financial figures, stock acquisitions, and vesting of restricted stock units.

Bio-Rad Laboratories FY26 Results: Sales guidance affirmed at $2.51B-$2.60B

https://scanx.trade/stock-market-news/companies/bio-rad-laboratories-fy26-results-sales-guidance-affirmed-2-51b-2-60b/55375849
Bio-Rad Laboratories reported a 0.5% increase in Q3 FY26 revenue to $656 million, marking its first currency-neutral growth for the year. The Clinical Diagnostics segment saw a 2.7% rise, while Life Science sales dipped 2.8%, though grew 2.5% excluding Process Chromatography. The company reaffirmed its full-year 2026 sales guidance of $2.506 billion to $2.596 billion, despite the midpoint being slightly below analyst estimates.
Advertisement

BIO.B SEC Filings, May-Sep 2026 - BIO-RAD LABORATORIES, INC. Filing Archive

https://www.stocktitan.net/sec-filings/BIO.B/page-2.html
This article provides an archive of SEC filings for Bio-Rad Laboratories, Inc. (BIO.B) from May to September 2026. It details various insider trading activities, including RSU vestings and stock sales by executives and directors, and also covers quarterly financial results for Q2 2026, highlighting profit offsets by fair-value losses and a significant restructuring plan. The filings include Form 4, 8-K, and 10-Q reports, each summarized with AI-generated insights.

Bio-Rad Laboratories, Inc. (BIO) Seasonal returns chart

https://uk.finance.yahoo.com/quote/BIO/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for Bio-Rad Laboratories, Inc. (BIO). It shows the average monthly price return for the company's stock between 2016 and 2026. The page also provides current stock information, including its latest price and after-hours trading.

With awards vesting 25% yearly, Bio-Rad (BIO) COO acquires 1,869 shares.

https://www.stocktitan.net/sec-filings/BIO/form-4-bio-rad-laboratories-inc-insider-trading-activity-8a0a9099a0c0.html
Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, Inc. (BIO), acquired 1,869 shares of Class A common stock on October 24, 2026, as restricted stock units (RSUs) vested. Following the transaction, DiVincenzo holds 3,740 restricted stock units, which vest at 25% per year over four years, and 2,881 shares of Bio-Rad A Common Stock. The acquisition involved the withholding of 951 shares at $369.95 per share to cover tax liabilities.

Bio-Rad Laboratories, Inc. (BIO.B) Führung & Management Team Analyse

https://simplywall.st/de/stocks/us/pharmaceuticals-biotech/nyse-bio.b/bio-rad-laboratories/management
This article provides an analysis of Bio-Rad Laboratories, Inc.'s management and leadership team, including CEO Norman Schwartz's tenure, compensation, and ownership stake. It details recent management changes, such as new executive appointments and the passing of co-founder Alice N. Schwartz. The report also discusses the company's financial performance, particularly its significant equity holding in Sartorius AG and the impact of market fluctuations on its earnings.

Form 4 BIO-RAD LABORATORIES: Sedat Evran (EVP, Global Supply Chain) For: 20 October By Investing.com

https://za.investing.com/news/stock-market-news/form-4-biorad-laboratories-sedat-evran-evp-global-supply-chain-for-20-october-93CH-4521058
This article reports on a Form 4 filing for Bio-Rad Laboratories concerning Sedat Evran, EVP, Global Supply Chain, for October 20. The filing is an official disclosure of insider transactions involving company stock. The article provides the basic announcement without further details on the transaction itself.
Advertisement

Form 4 BIO-RAD LABORATORIES: Sedat Evran (EVP, Global Supply Chain) For: 20 October

https://uk.investing.com/news/stock-market-news/form-4-biorad-laboratories-sedat-evran-evp-global-supply-chain-for-20-october-93CH-4927051
This article reports on a Form 4 filing for Bio-Rad Laboratories concerning Sedat Evran, EVP, Global Supply Chain, for transactions that occurred on October 20th. The filing indicates insider trading activity for the company.

Bio-Rad Laboratories, Inc. Class B (BIO.B) Earnings Dates, Call Summary & Reports

https://www.tipranks.com/stocks/bio.b/earnings
This article provides a comprehensive overview of Bio-Rad Laboratories, Inc. Class B (BIO.B) earnings, including upcoming report dates, historical data, and analyst consensus. The next earnings report is estimated for November 4, 2026, after market close, with a consensus EPS forecast of 2.23 for Q3 2026. The report also details past earnings performance and the stock's price changes around previous announcements.

Sedat Evran Reports Vesting of 1,044 Bio-Rad RSUs with Tax Share Disposal on October 20, 2026

https://kalkinemedia.com/us/news/announcements/sedat-evran-reports-vesting-of-1044-bio-rad-rsus-with-tax-share-disposal-on-october-20-2026
Sedat Evran, EVP of Global Supply Chain at Bio-Rad Laboratories, reported the vesting of 1,044 restricted stock units (RSUs) on October 20, 2026. Simultaneously, 487 Bio-Rad Class A common stock shares were sold at $354.5 each to cover tax withholding obligations. After these transactions, Evran directly holds 4,160.12 shares of Bio-Rad Class A common stock, with 1,044 RSUs remaining outstanding from an initial grant in 2023.

Quick ratio of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA

https://www.tradingview.com/symbols/HAM-BUWA/financials-statistics-and-ratios/quick-ratio/
The article displays the quick ratio for Bio-Rad Laboratories, Inc. Class A (HAM:BUWA) as presented on TradingView. It provides a financial overview of the company on the Hamburg Stock Exchange, noting that the market was closed with no trades. The quick ratio value and its change are mentioned as being "Made by humans."

Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026

https://investingnews.com/bio-rad-to-report-third-quarter-2026-financial-results-on-wednesday-november-4-2026/
Bio-Rad Laboratories, Inc. announced it will release its third-quarter 2026 financial results on Wednesday, November 4, 2026, after market close. The company will host a conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) to discuss these results, with details provided for participation and webcast access. Bio-Rad is a global leader in life science research and clinical diagnostics products, with approximately $2.6 billion in revenues in 2025.
Advertisement

Weekly Recap: Bio-Rad growth and margin plan and digital PCR expansion

https://www.tradingview.com/news/tradingview:b8db25bd80f31:0-weekly-recap-bio-rad-growth-and-margin-plan-and-digital-pcr-expansion/
Bio-Rad Laboratories, Inc. (BIO) has announced a multi-year plan focused on driving growth, expanding margins, and strengthening free cash flow. The strategy leverages its digital PCR franchise, including Droplet Digital PCR and new QX700 units from Stilla, alongside portfolio discipline and selective acquisitions. This plan aims to enhance its market position and financial performance.

Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

https://investingnews.com/bio-rad-to-participate-in-fireside-chat-during-bernstein-insights-healthcare-leaders-and-disruptors-3rd-annual-forum/
Bio-Rad Laboratories, Inc. announced that its CFO, Roop K. Lakkaraju, will participate in a fireside chat at the Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on September 24, 2026. A live webcast and replay of the event will be available on Bio-Rad's Investor Relations website. Bio-Rad is a global leader in life science research and clinical diagnostics products.

[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity

https://www.stocktitan.net/sec-filings/BIO/form-4-bio-rad-laboratories-inc-insider-trading-activity-dfe6b5474551.html
Jonathan P. DiVincenzo, President & COO of BIO-RAD LABORATORIES, INC. (BIO), filed a Form 4 detailing insider trading activity. The filing indicates the exercise/conversion of 1,712 shares, with 6,326 Restricted Stock Units granted, vesting over four years. Holdings after the transaction include 11,464 Restricted Stock Unit contracts and 1,963 shares of Bio-Rad A Common Stock.

BIO-RAD LABORATORIES, INC. Executive Courtney C. Enloe Exercises 1,453 Stock Options at $0 (NYSE: BIO)

https://kalkinemedia.com/us/news/announcements/bio-rad-laboratories-inc-executive-courtney-c-enloe-exercises-1453-stock-options-at-0-nyse-bio
Courtney C. Enloe, an executive at BIO-RAD LABORATORIES, INC. (NYSE: BIO), exercised options for 1,453 shares at no cost between September 5 and September 6, 2026. Following these transactions, Enloe's holdings include 1,652 shares and 1,536 derivative securities, with an additional 2,876 derivative securities granted on September 4, 2026. The award on September 4 represented approximately 100% of Enloe's resulting derivative securities holdings.

1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld

https://www.stocktitan.net/sec-filings/BIO/form-4-bio-rad-laboratories-inc-insider-trading-activity-daac335451f9.html
Bio-Rad Laboratories, Inc. (NYSE: BIO) executive vice president and general counsel Courtney C. Enloe had 1,453 restricted stock units (RSUs) vest, which were converted into Class A common stock. On September 4, 2026, Enloe was also granted 2,876 new RSUs vesting over four years. A total of 551 shares were withheld at $386.11 per share to cover exercise price or tax liabilities related to the vesting.
Advertisement

Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain

https://www.morningstar.com/company-reports/1498465-bio-rads-timing-for-revenue-growth-recovery-remains-uncertain
Bio-Rad Laboratories, a leader in life sciences research and clinical diagnostics, operates on a "razor-and-blade" model with consumables accounting for 70% of sales. The company maintains niche market leadership in diagnostic quality controls, antigens, and digital PCR. This report by Jay Lee on September 7, 2026, suggests continued uncertainty regarding the timing of its revenue growth recovery.

Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference

https://investingnews.com/bio-rad-to-participate-in-fireside-chat-during-wells-fargo-s-21st-annual-healthcare-conference/
Bio-Rad Laboratories, Inc. announced that its CFO, Roop K. Lakkaraju, will participate in a fireside chat at Wells Fargo's 21st Annual Healthcare Conference on September 9, 2026. A live webcast and replay of the event will be available on Bio-Rad's investor relations website. Bio-Rad is a global leader in life science research and clinical diagnostics products, with approximately 7,400 employees and $2.6 billion in revenues in 2025.

Bio-Rad Laboratories stock hits 52-week high at 394.22 USD

https://ca.investing.com/news/stock-market-news/biorad-laboratories-stock-hits-52week-high-at-39422-usd-93CH-4819871
Bio-Rad Laboratories Inc. (BIO) stock recently hit a 52-week high of $394.22, demonstrating strong market performance with significant year-to-date and 1-year gains. Despite surpassing second-quarter earnings and revenue expectations, the company's shares experienced an after-hours dip due to a cautious outlook and challenges in the life sciences sector and China. InvestingPro analysis suggests the stock is slightly undervalued, with potential for continued growth.

Why Bio-Rad Laboratories (BIO) Is Up 6.7% After Restructuring Move Amid Mixed Segment Trends

https://www.sahmcapital.com/news/content/why-bio-rad-laboratories-bio-is-up-67-after-restructuring-move-amid-mixed-segment-trends-2026-08-22
Bio-Rad Laboratories' stock is up 6.7% following a restructuring announcement aimed at cost savings and improving operating margins by 2027. This move comes as the company experiences continued growth in its digital PCR business but faces softer demand in its Life Science segment and maintains a cautious outlook for 2026. The restructuring is a key factor in the investment narrative, addressing concerns about gross margin pressure and low returns, but investors should be aware of the risks if savings fall short or market conditions remain weak.

Return on invested capital % of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA

https://www.tradingview.com/symbols/HAM-BUWA/financials-statistics-and-ratios/return-on-invested-capital/
This article displays the "Return on invested capital %" for Bio-Rad Laboratories, Inc. Class A (HAM:BUWA). The content is primarily a data page from TradingView, focusing on the financial metric for the specified company listed on the Hamburg Stock Exchange.
Advertisement

EBITDA per share of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA

https://www.tradingview.com/symbols/HAM-BUWA/financials-statistics-and-ratios/ebitda-per-share/
The article focuses on the EBITDA per share information for Bio-Rad Laboratories, Inc. Class A (HAM:BUWA) as presented on TradingView. It appears to be a page from a financial data platform, providing an overview of the company's financials for users. The content includes navigation and legal disclaimers related to the financial data provided.

Bio-Rad Laboratories stock hits 52-week high at $365.68

https://www.investing.com/news/company-news/biorad-laboratories-stock-hits-52week-high-at-36568-93CH-4867655
Bio-Rad Laboratories Inc. (NYSE:BIO) stock reached a new 52-week high of $365.68, currently trading at $365.80 with a market capitalization of $9.57 billion. The company has seen a 24.22% increase over the past year and a 29.71% return in the last six months, driven by positive investor sentiment and better-than-expected Q2 earnings and revenue. Despite a cautious outlook for the life sciences sector, the stock is considered undervalued relative to its Fair Value.

Bio Rad Laboratories (BIO) Issues Flat Revenue Guidance, Is It Too Far Above Fair Value?

https://www.sahmcapital.com/news/content/bio-rad-laboratories-bio-issues-flat-revenue-guidance-is-it-too-far-above-fair-value-2026-08-12
Bio-Rad Laboratories (BIO) has seen a sharp increase in its stock price over the last 90 days, despite recent flat revenue guidance and a significant long-term decline in shareholder return. The company is currently trading above its fair value estimate of $293, driven by robust order growth in biopharmaceutical research, but faces challenges from softer instrument demand. Investors are advised to review the data to form their own views on the company's valuation.

Bio-Rad Laboratories (NYSE: BIO) Q2 profit offset by H1 fair-value losses

https://www.stocktitan.net/sec-filings/BIO/10-q-bio-rad-laboratories-inc-quarterly-earnings-report-159e3f014b40.html
Bio-Rad Laboratories reported flat net sales of $651.0 million in Q2 2026, with a significant net income of $371.4 million driven by a large fair-value gain on equity securities and a loan receivable, primarily related to its Sartorius investment. However, the first half of 2026 saw a net loss of $155.7 million due to a $280.2 million fair-value loss on these assets. The company announced a restructuring plan starting in July 2026, expected to incur $80-90 million in pre-tax charges through 2027, and maintains strong liquidity with $1.62 billion in cash and no borrowings on its credit facility.

Bio-Rad earnings up next: Can diagnostics stabilize amid headwinds? By Investing.com

https://ng.investing.com/news/earnings/biorad-earnings-up-next-can-diagnostics-stabilize-amid-headwinds-93CH-2637605
Bio-Rad Laboratories Inc. is set to report its second-quarter earnings, with analysts anticipating a decline in both earnings per share and revenue year-over-year. Investors will be closely watching for signs of stabilization in the company's Life Science and Clinical Diagnostics segments, which faced headwinds in the first quarter due to a slowdown in research and geopolitical tensions. Despite a lowered full-year outlook, the stock has benefited from broader sector momentum in the life sciences, but the upcoming report will determine if the company has overcome its challenges.
Advertisement

Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026

https://investingnews.com/bio-rad-to-report-second-quarter-2026-financial-results-on-tuesday-august-4-2026/
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced it will report its second-quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. The company will host a conference call at 2:00 PM Pacific Time to discuss these results, with a live webcast available on its investor relations website. Bio-Rad, a global leader in life science research and clinical diagnostics, generated $2.6 billion in revenues in 2025.

Trading the Move, Not the Narrative: (BIO) Edition

https://news.stocktradersdaily.com/news_release/38/Trading_the_Move,_Not_the_Narrative:_BIO_Edition_072826095001_1785289801.html
This article provides an AI-generated analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), focusing on institutional trading strategies based on sentiment and price positioning. It outlines specific long and short trading strategies with entry zones, targets, and stop losses, along with a multi-timeframe signal analysis for near, mid, and long-term horizons. The analysis emphasizes strong near and mid-term sentiment, suggesting potential for extended positive momentum.

Bio-Rad Laboratories EVP Eva Anette Engelhardt Reports Restricted Stock Unit Vesting and Share Sale

https://kalkinemedia.com/us/news/announcements/bio-rad-laboratories-evp-eva-anette-engelhardt-reports-restricted-stock-unit-vesting-and-share-sale
Eva Anette Engelhardt, EVP and President of Bio-Rad Laboratories' Clinical Diagnostics Group, recently acquired 246 shares of Class A common stock through restricted stock unit vesting. Concurrently, she sold 89 shares at $314.46 each. This transaction offers transparency into executive compensation and stock ownership practices at the company.

Bio Rad Laboratories (BIO) Stock Looks Fairly Valued After A 57% Slide

https://www.sahmcapital.com/news/content/bio-rad-laboratories-bio-stock-looks-fairly-valued-after-a-57-slide-2026-07-22
Bio-Rad Laboratories (BIO) stock has declined 57.1% over five years, yet its current price of US$301.70 appears fairly valued according to Discounted Cash Flow (DCF) estimates which suggest an intrinsic value of $291 per share. However, its P/E ratio of 47.8x is higher than the Life Sciences industry average of 38.0x, indicating it might be overvalued based on earnings. The launch of Vericheck ddPCR kits could support future demand, but investors are already paying a premium.

ETFs Investing in Bio-Rad Laboratories, Inc. Class A Stocks

https://www.tradingview.com/symbols/BOATS-BIO/etfs/
This article lists various Exchange Traded Funds (ETFs) that hold Bio-Rad Laboratories, Inc. Class A stocks, sorted by market value. It provides key financial data for each ETF, including issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and 3-year total return. The information aims to help investors identify opportunities and understand the risk profiles associated with these ETFs.
Advertisement

Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate

https://www.sahmcapital.com/news/content/bio-rad-laboratories-bio-launches-new-ddpcr-kits-following-a-fair-value-debate-2026-07-12
Bio-Rad Laboratories (BIO) has launched new QX700 System-compatible Vericheck ddPCR Kits for quality control in cell and gene therapy, potentially impacting investor assessment of the stock. While the company's shares show modest recent momentum and analyst targets are largely met, Simply Wall St's narrative suggests a fair value of $293, making the current price of $296.11 slightly overvalued. The fair value assessment is based on strong recurring consumables sales and an optimistic earnings multiple, though softer instrument demand and policy shifts in China pose potential challenges.

(BIO) Volatility Zones as Tactical Triggers

https://news.stocktradersdaily.com/news_release/149/BIO_Volatility_Zones_as_Tactical_Triggers_070626034001_1783323601.html
This article analyzes Bio-rad Laboratories Inc. Class A (NYSE: BIO) using AI models, identifying a neutral sentiment across all time horizons. It outlines three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis highlights an exceptional 37.5:1 risk-reward setup, targeting a 10.8% gain against a 0.3% risk.

Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued

https://www.sahmcapital.com/news/content/bio-rad-laboratories-bio-following-ddpcr-expansion-narrative-looks-fully-valued-2026-06-28
Bio-Rad Laboratories (BIO) has experienced recent stock momentum, with shares up 6.5% over the past week, although it's still down 54.9% over five years. The stock currently trades slightly above its narrative fair value of $293, driven by expectations of growth from its ddPCR platforms and Stilla Technologies acquisition. Despite this, the company faces challenges from softer instrument demand and Clinical Diagnostics headwinds in markets like China, making its valuation appear stretched when considering its P/E ratio of 47.7x compared to a fair ratio of 16.7x.

Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449)

https://www.tradingview.com/symbols/LSX-862449/forecast-actuals-and-estimates/
This article provides an overview of Bio-Rad Laboratories, Inc. Class B (LSX:862449) financial data, analyst estimates, and frequently asked questions. It details past earnings, revenue, net income, and future earnings expectations, along with share price forecasts from analysts. The report also covers employee count and EBITDA information for the company.

Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (FWB:BUW)

https://www.tradingview.com/symbols/FWB-BUW/forecast-actuals-and-estimates/
This article provides financial actuals and estimates for Bio-Rad Laboratories, Inc. Class B (FWB: BUW), detailing income statement, balance sheet, cash flow, and valuation metrics. It includes analyst forecasts, historical price movements, earnings reports, dividend policy, employee count, and EBITDA figures. The information is designed to help investors research and compare performance trends.
Advertisement

Bio-Rad Laboratories, Inc. Class A Actuals & Estimates (NYSE:BIO)

https://www.tradingview.com/symbols/NYSE-BIO/forecast-actuals-and-estimates/
This article provides an overview of Bio-Rad Laboratories, Inc. (NYSE: BIO) stock, including its current price, market capitalization, and historical performance. It also details actual and estimated financial data, analyst forecasts for its future price, and information regarding upcoming earnings reports and dividends.

Price-Driven Insight from (BIO) for Rule-Based Strategy

https://news.stocktradersdaily.com/news_release/151/Price-Driven_Insight_from_BIO_for_Rule-Based_Strategy_062526023202_1782369122.html
This article provides a price-driven analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It identifies a significant risk-reward short setup and outlines three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.

How Stronger Results and Institutional Selling At Bio-Rad Laboratories (BIO) Has Changed Its Investment Story

https://www.sahmcapital.com/news/content/how-stronger-results-and-institutional-selling-at-bio-rad-laboratories-bio-has-changed-its-investment-story-2026-06-18
Bio-Rad Laboratories recently reported improved financial results with year-over-year revenue and net profit growth, yet institutional investors, notably First Eagle Investment, have significantly reduced their holdings. This divergence between strengthening financials and declining institutional ownership, alongside neutral to weak technical indicators, prompts questions about the investment narrative. The article suggests that while operational performance is improving, market confidence for BIO may remain fragile, despite a projected fair value of $293.00.

(BIO) as a Liquidity Pulse for Institutional Tactics

https://news.stocktradersdaily.com/news_release/9/BIO_as_a_Liquidity_Pulse_for_Institutional_Tactics_060226115001_1780458601.html
This article provides a detailed analysis of Bio-Rad Laboratories Inc. Class A (NYSE: BIO), highlighting its potential as a liquidity pulse for institutional tactics. It identifies a strong risk-reward setup targeting a 12.2% gain against 0.3% risk and outlines three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis also includes multi-timeframe signal analysis, indicating strong near-term and mid-term sentiment for the stock.

(BIO) as a Liquidity Pulse for Institutional Tactics

https://news.stocktradersdaily.com/news_release/1/BIO_as_a_Liquidity_Pulse_for_Institutional_Tactics_060226115001_1780458601.html
The article analyzes Bio-Rad Laboratories Inc. Class A (NYSE: BIO) with a focus on institutional trading strategies. It highlights a strong sentiment, an exceptional risk-reward setup targeting a 12.2% gain, and provides AI-generated trading signals for various time horizons and risk profiles. The analysis includes position trading, momentum breakout, and risk-hedging strategies, alongside support and resistance levels.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement